Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Genzyme signs manufacturing deal with Hospira
February 2010
SHARING OPTIONS:

CAMBRIDGE, Mass.—Biotechnology company Genzyme Corp. is contracting manufacturing for its key products to Hospira Inc. for an undisclosed amount, the company announced last month. The deal involves the manufacturing of the genetic disorder drugs Cerezyme, Fabrazyme, Myozyme and Thyrogen and follows a series of manufacturing problems at the company's facility in the Boston neighborhood of Allston. In June, Genzyme shut down the manufacturing plant to clean up viral contamination that had been slowing down production of two key drugs. The virus was not harmful to people and production restarted in September, though it cost the company millions in revenue. The deal with Hospira, which makes drug and medication delivery systems, calls for the initial term to expire on Dec. 31, 2015. There are options for a two-year extension. The deal is still subject to regulatory approval for manufacturing the products.


Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.